Yangling Jinhai Biotechnology Co., Ltd. announced that it will raise CNY 80,000,000 in an equity round of funding on March 15, 2021. The transaction will involve participation from new investor Shanghai Runling Investment Partnership for CNY 60,000,000 and returning investor Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) for CNY 25,000,000. Post the closing, the stake of Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) will increase from 55% to 76.07% and Shanghai Runling Investment Partnership will hold 21.43% stake in the company. The registered capital of the company is CNY 100,000,000. Post the completion, the registered capital of the company will become CNY 200,000,000, and CNY 40,000,000 will be included in the capital reserve. The transaction has been approved at the 23rd meeting of the third board of directors of Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).